



GAMARRA & GONZALES ASOCIADOS S.C.

Date May 07", 2020

**The Board of Directors,
Sun Pharmaceutical Industries Limited (Parent Company)
Mumbai, India.**

On the basis of information provided and records verified, we hereby certify that for the year ended December 31, 2019,

- I. There has been due, material & substantive compliance with all the laws, orders, regulations and other legal requirements of the Central, State and other Government and Local Authorities concerning the business and affairs of the subsidiary Company namely SUN PHARMACEUTICAL PERU SAC and in particular.
- II. All returns and forms have been filed and particulars furnished within the stipulated time to the Tax Administration and/or Authorities as required by the Corporation Act (Ley General de Sociedades) and the Rules made there under.
- III. The Company has not committed any default in preparing and filing the Annual Accounts and the Annual Returns with the Tax Administration and/or Authorities as required by the Corporation Act (Ley General de Sociedades) and the Rules made there under.

This Certificate is given by the undersigned with full knowledge that, on its faith and strength, reliance is placed by the Board of Directors of the parent Company.

GAMARRA MEDRANO ANTONIO N.

Certified Public Accountant

Registration No. 232

Registration No. 28787

Independent Auditor

***SUN PHARMACEUTICAL PERU
S.A.C.***

***FINANCIAL STATEMENTS
AS ON DECEMBER 31, 2019***

CONTENT:

Report of independent auditors

Financial Statements:

Statement of Financial Position

Income Statement

Statement of Changes in Equity

Cash Flow Statement

Notes to the Financial Statements



REPORT OF INDEPENDENT AUDITORS

May 04, 2020

**To the Shareholders and Directors
SUN PHARMACEUTICAL PERU SAC.**

We have audited the attached Balance Sheet of SUN PHARMACEUTICAL PERU SAC., as on December 31, 2019 with the related Income Statement, Statement of Changes in Equity and Cash Flows for the year then ended; the arrangement of such Financial Statements are the Company's Management responsibility. Our responsibility is to express an opinion on these Financial Statements based on our audit.

Our audit was made in accordance with generally accepted Auditing Standards in Peru. Those standards require that we plan and perform our work in order to obtain reasonable guarantee that the Financial Statements are free of material misstatement. An audit includes an assessment based on selective evidence supporting the amounts and disclosures in the Financial Statements. An audit also includes assessing the accounting principles applied, and the significant estimates made by the Management; as well as evaluating an overall presentation of the Financial Statements. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the attached Financial Statements present fairly, in all material respects, the financial position of the company SUN PHARMACEUTICAL PERU SAC., for the year ended December 31, 2019, the results of its operations and cash flows for the year then ended in accordance with the generally accepted Accounting Principles.

Endorsed by:

GAMARRA MEDRANO ANTONIO N.
*Certified Public Accountant
Registration No. 232
Registration No. 28787
Independent Auditor*

SUN PHARMACEUTICAL PERU SAC

BALANCE SHEET AS AT DECEMBER 31, 2019

<i>Notes</i>	<i>As at December 31, 2019</i>	<i>As at December 31, 2018</i>
	<i>Nuevos Soles</i>	<i>Nuevos Soles</i>
EQUITY AND LIABILITIES		
Shareholders' Funds		
Capital Stock	S/.1,500.00	S/.1,500.00
Reserves and Surplus	S/-.7,772,398.43	S/-.7,851,547.00
	S/-.7,770,898.43	S/-.7,850,047.00
Current Liabilities		
Other Accounts Payable	S/.216,558.00	S/.0.00
Trade Account payable related	S/-.7,566,778.77	S/-.7,855,086.00
	S/-.7,783,336.77	S/-.7,855,086.00
Total	S/.12,438.34	S/.5,039.00
ASSETS		
Non Current Assets		
Fixed Assets		
Tangible Assets	S/.4,031.20	S/.5,039.00
Current Assets		
Cash and Cash Equivalents	S/.8,407.14	S/.0.00
Other Current Assets	S/.0.00	S/.0.00
	S/-.8,407.14	S/.0.00
Total	S/.12,438.34	S/.5,039.00

The accompanying notes are part of the financial statements

ASOCIADOS S.C.

SUN PHARMACEUTICAL PERU SAC

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED DECEMBER 31, 2019

	<i>Notes</i>	<i>Year Ended December 31, 2019</i>		<i>Year Ended December 31, 2018</i>	
		<i>Nuevos Soles</i>	<i>Nuevos Soles</i>	<i>Nuevos Soles</i>	<i>Nuevos Soles</i>
<i>Personnel Expenses</i>		<i>S/.0.00</i>		<i>S/.0.00</i>	
<i>Marketing Sales and Distribution Expenses</i>		<i>S/.0.00</i>		<i>S/.0.00</i>	
<i>Other Expenses</i>	<i>10</i>	<i>S/.962.63</i>		<i>S/.900.80</i>	
<i>Depreciation</i>	<i>11</i>	<u><i>S/.1,007.80</i></u>	<u><i>S/.1,970.43</i></u>	<u><i>S/.1,076.20</i></u>	<u><i>S/.1,977.00</i></u>
<i>Operating Profit</i>			<u><i>S/.-1,970.43</i></u>		<u><i>S/.-1,977.00</i></u>
<i>Exchange Gain / (Loss) - Net</i>			<u><i>S/.81,119.00</i></u>		<u><i>S/.-38,608.00</i></u>
<i>Profit Before Tax</i>			<u><i>S/.79,148.57</i></u>		<u><i>S/.-40,585.00</i></u>
<i>Tax Expenses</i>					
<i>Current Tax</i>					
<i>Deferred Tax Expenses</i>			<u><i>S/.0.00</i></u>		<u><i>S/.0.00</i></u>
<i>Profit for the Year</i>			<u><u><i>S/.79,148.57</i></u></u>		<u><u><i>S/.-40,585.00</i></u></u>

The accompanying notes are part of the financial statements

ASOCIADOS S.C.

SUN PHARMACEUTICAL PERU SAC

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY YEAR ENDED DECEMBER 31, 2019

Shareholders' Name	Opening Balance		Addition / (Deletion)		Closing Balance	
	No. of Shares	Nuevos Soles	No. of Shares	Nuevos Soles	No. of Shares	Nuevos Soles
SUN PHARMACEUTICAL INDUSTRIES LTD	149	S/.1,490			149	S/.1,490
MILMET PHARMA LTD	1	S/.10			1	S/.10
Total Capital Stock	150	S/.1,500	0	S/.0	150	S/.1,500
Year ended December 31, 2018						S/.1,500

The accompanying notes are part of the financial statements

ASOCIADOS S.C.

SUN PHARMACEUTICAL PERU SAC

CASH FLOW STATEMENT FOR THE YEAR ENDED DECEMBER, 31, 2019

	Year Ended December 31, 2019		Year Ended December 31, 2018	
	Nuevos Soles	Nuevos Soles	Nuevos Soles	Nuevos Soles
CASH FLOW FROM OPERATING ACTIVITIES				
<i>Profit Before Tax</i>		S/.79,148.57		S/.-40,585.00
Adjustment for:				
<i>Depreciation Expenses</i>	S/.1,007.80		S/.1,076.20	
<i>Provision for Doubtful Trade Receivables and Advances</i>				
<i>Profit on Sales of Fixed Assets</i>	S/.0.00		S/.0.00	
<i>Interest Income</i>	S/.-81,119.00	S/.-80,111.20	S/.0.00	S/.1,076.20
Operating Profit Before Working Capital Changes		S/.-962.63		S/.-39,508.80
Changes in Working Capital:				
<i>Increase / (Decrease) Trade Payables</i>	S/.216,558.00			
<i>Increase / (Decrease) Other Current Liabilities</i>	S/.-71,749.23			
<i>(Increase) / Decrease Other Current Assets</i>	S/.0.00	S/.144,808.77		S/.0.00
Cash Generated from Operations		S/.143,846.14		S/.-39,508.80
<i>Income Tax Paid</i>		S/.0.00		S/.0.00
Net Cash Flow from Operating Activities		S/.143,846.14		S/.-39,508.80
CASH FLOW FROM INVESTING ACTIVITIES				
<i>Interest Income</i>		S/.81,119.00		S/.0.00
Net Cash Flow Generated from / (Used in) Investing Activities		S/.81,119.00		S/.0.00
NET INCREASE IN CASH AND EQUIVALENTS		S/.224,965.14		S/.-39,508.80
CASH AND EQUIVALENTS AT BEGINNING OF THE YEAR		S/.-39,508.80		
CASH AND EQUIVALENTS AT END OF THE YEAR		S/.185,456.34		S/.-39,508.80

The accompanying notes are part of the financial statements

SUN PHARMACEUTICAL PERU S. A.C.

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2019

03. OBJECTIVE, ACTIVITIES AND LEGAL ASPECT

SUN PHARMACEUTICAL PERU S.A.C. was incorporated on June 27, 2006 in compliance with the legal formalities and in accordance with the General Law of Commercial Companies duly registered on the Register of Legal Entities of Lima, on January 27, 2006 on item No. 11703068 and amendments.

The main activity of the company is devoted to the commercialization of pharmaceutical products.

Within the corporate purpose, acts related to the activities described in the preceding paragraphs that contribute to its goals achievement are included. To comply with the corporate purpose, the company may perform all legal acts and contracts without restriction or limitation

The activity of SUN PHARMACEUTICAL PERU S.A.C. is governed by the New General Law of Commercial Companies and as provided in the ARTICLES and rules of incorporation and amendments.

04. SIGNIFICANT ACCOUNTING POLICIES

The most significant accounting principles and policies applied for registration of operations and arrangement of Financial Statements are as follows:

- a) The preparation and Financial Statements in accordance with generally accepted accounting principles in Peru, requires Management to make estimates and assumptions to determine the amounts of assets and liabilities and the amounts of revenues and expenses, and of contingent assets and liabilities at the date of the financial statements. If these estimates and assumptions vary in the future as a result of changes in circumstances and conditions under which they were based, the effect of such changes is recognized in profit or loss at the time such changes are identified and their effects. The main estimates related to financial statements correspond: i) estimate of allowance for doubtful accounts; ii) allowances for impairment of inventories; iii) estimate of useful life assigned to property, plant and equipment; iv) the recoverability of income tax.

- b) *Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment, if any. The initial cost comprises its purchase price, and any other costs directly attributable to locating and rendering the assets fit to use. Disbursements incurred after assets have been put to use, such as repairs and the cost of maintenance and refurbishment are charged to results of period in which the costs are incurred. If it can be demonstrated clearly that such disbursement will result in future benefits deriving from use assets beyond their original performance standard, these are capitalized as an additional cost to assets. Repairs and maintenance costs are recognized in the results of period as incurred. An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Statement of profit and loss when the asset is derecognized.*
- c) *Foreign currency transactions: Functional currency and presentation currency, Company prepares and presents its financial statements in Soles, which corresponds to its functional currency. The functional currency corresponds to primary economic environment in which the Company operates. Transactions and balances, transactions in currencies other than the functional currency are translated into the functional at the exchange rate prevailing at the date of the transactions. Differences due to adjustment of balances of assets and liabilities in foreign currencies, recorded at exchange rate when operations arise and exchange rate at the date of balance sheet are recognized in the results of period.*

05. CASH AND BANKS.

This item consists of:

AS ON DECEMBER 31
In Soles

<u>DETAIL</u>	<u>2 0 1 9</u>	<u>2 0 1 8</u>
Bank	<u>8,407</u>	<u>0</u>
	<u><u>8,407</u></u>	<u><u>0</u></u>

06. PROPERTY, PLANT AND EQUIPMENT

An important part of the Financial Statements consists of:

AS ON DECEMBER 31

In Soles

TYPE OF ASSETS	COSTS	CUMULATIVE DEPRECIATION	AS ON DECEMBER 31	
			2019	2018
Various equipment	10,900	-6,869	4,031	5,039
	<u>10,900</u>	<u>-6,869</u>	<u>4,031</u>	<u>5,039</u>

07. OTHER ACCOUNTS PAYABLE

Formed by:

AS ON DECEMBER 31

In Soles

<u>DETAIL</u>	<u>2019</u>	<u>2018</u>
Bills payable in national currency	216,558	99,924
	<u>216,558</u>	<u>99,924</u>

08. ACCOUNTS PAYABLE - RELATED

Formed by:

AS ON DECEMBER 31

In Soles

<u>DETAIL</u>	<u>2019</u>	<u>2018</u>
Accounts with various third parties:		
Acoounts Payable - related	7'566,779	7'755,162
	<u>7'566,779</u>	<u>7'755,162</u>

09. EQUITY

Formed by:

	AS ON DECEMBER 31	
	In Soles	
DETAIL	2019	2018
Equity Capital	1,500	1,500
Retained Earnings	-7'851,547	-7'810,962
Net Income (loss) for the Year	70,149	-40,585
	-7'770,898	-7'850,047

At the time of its founding of the Company in 2006, it was incorporated with a capital of S/.1,500.00 soles, which after the adjustment of its accounting formalization, according to the general balance of 2018, the capital stock was made up of S/. 1,500.00 soles, representing 150 units of common shares and a nominal value of a new sol (S/. 10.00) per share.

.According to the general balance sheet for 2019, the capital stock is made up of S / 1,500.00 soles, which are represented in 150 units of common stock and a nominal value of one sol (S/. 10.00) per share. Because the Company has had losses from the period 2019 and 2018, its equity is shown in negative expecting the third year to be positive.

10. INCOME TAX

According to Superintendency Resolution N° 271-2019/Sunat of 12/27/2019, the provisions and forms the annual sworn declaration of income tax and financial transaction tax for the 2019 taxable year are approved which Through the Consolidated Text of the Law on Income Tax, Supreme Decree No. 179-2004-EF and amendments, rules are established as approved by Supreme Decree No. 054-99-EF, hereinafter TUO, and related standards regulating the Income Tax, as amended by Law No. 27356, 27386 and 27394 and Law No. 27513 and Law No. 27615. This standard has been regulated by Supreme Decree No. 122-94-EF, modified by SD 194-99-EF and S.D. 045-2001-EF. That with Superintendenc y Resolution No. 011-2018 / SUNAT, provisions and forms for the annual sworn declaration of income tax are approved and Superintendency Resolution No. 015-2019 / sunat approving the provisions and forms for the annual tax return for income tax and taxes on the financial transactions of the taxable year 2018.

SUN PHARMACEUTICAL PERU SAC

21. FIXED ASSETS Particulars	Dep. Rate	Gross Block (At Cost)		Depreciation / Amortisation / Impairment			Net Block	
		As At 01.01.19	As At 31.12.19	As at 01.01.19	For the Year	On Deletions For the Year	As at 31.12.19	As at 31.12.18
Tangible Assets								
Office Equipments	10%	10,900	10,900	5,861	1,008	6,869	4,031	5,039
Total		10,900	10,900	5,861	1,008	6,869	4,031	5,039
Previous Year 2018								

G & G
 ASOCIADOS S.C.

SUN PHARMACEUTICAL PERU SAC
BREAK UP ANALYSIS - BALANCE SHEET

	Notes	As at December 31, 2019		As at December 31, 2018	
		Nuevos Soles	Nuevos Soles	Nuevos Soles	Nuevos Soles
RESERVES AND SURPLUS	9		S/.-7,772,398.43		S/.-7,851,547.00
<i>Surplus in Income Statement</i>			S/.-7,772,398.43		S/.-7,851,547.00
<i>Opening Balance</i>		S/.-7,851,547.00		S/.-7,810,962.00	
<i>Add: Profit For the Period</i>		S/79,148.57		S/.-40,585.00	
CURRENT LIABILITIES			S/7,783,336.77		S/7,855,086.00
<i>Other Current Liabilities</i>			S/7,783,336.77		S/7,855,086.00
<i>Other Accounts Payable</i>	7	S/216,558.00		S/99,924.00	
<i>Trade Account payable related</i>	8	S/7,566,778.77		S/7,755,162.00	
NON CURRENT ASSETS			S/4,031.20		S/5,039.00
<i>Fixed Assets Gross Block</i>			S/10,900.00		S/5,039.00
<i>Office Equipments</i>	6	S/10,900.00		S/5,039.00	
<i>Accumulated Depreciation</i>			S/6,868.80		S/0.00
CURRENT ASSETS			S/8,407.14		S/0.00
<i>Cash and Cash Equivalents</i>			S/8,407.14		S/0.00
<i>Balances With Banks</i>			S/8,407.14		S/0.00
<i>On Current Nuevos Soles</i>	5	S/8,407.14			

ASOCIADOS S.C.

SUN PHARMACEUTICAL PERU SAC

BREAK UP ANALYSIS - PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED DECEMBER 31, 2019

	<i>Notes</i>	<i>Year Ended December 31, 2019</i>	<i>Year Ended December 31, 2018</i>
		<i>Nuevos Soles</i>	<i>Nuevos Soles</i>
Other Income			
Difference exchange rate - Gain		S/.81,119.00	
Difference exchange rate (Lost)			S/.38,608.00
Tota Other Income		S/.81,119.00	S/.38,608.00
Other Expenses			
Bank charges		S/.962.63	S/.232.00
Regulatory Filling Fees			S/.485.00
Other Misc. Expenses			S/.183.80
Total Other Expenses	10	S/.962.63	S/.900.80
Depreciations			
Office Equipments		S/.1,007.80	S/.1,076.20
Total Depreciations	11	S/.1,007.80	S/.1,076.20